Abliva Q3’20: Energizing Interactions

Research Note



Redeye believes the key takeaway from the recent quarter is the positive momentum in clinical and regulatory development for lead candidate KL1333. Abliva has also initiated preliminary discussions with a US clinical trial regarding a possible collaboration for non-core asset NeuroSTAT.


Niklas Elmhammer

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.